CHINA AND INDIA APPROVE NASAL COVID VACCINES

More than 100 mucosal vaccines against the disease are in development globally, and about 20 have reached clinical trials in humans, according to Airfinity, a health-analytics company in London. Data from a phase II trial of CanSino's inhaled vaccine found that, when given as a booster, the vac...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 609; no. 7927; p. 450
Main Author Waltz, Emily
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group 15.09.2022
Subjects
Antibodies
Clinical trials
Coronaviruses
COVID-19 vaccines
Disease transmission
Influenza
Mucosa
Nose
Severe acute respiratory syndrome coronavirus 2
Vaccines
Iran
China
Russia
India
Online AccessGet full text

Cover

More Information
Summary:More than 100 mucosal vaccines against the disease are in development globally, and about 20 have reached clinical trials in humans, according to Airfinity, a health-analytics company in London. Data from a phase II trial of CanSino's inhaled vaccine found that, when given as a booster, the vaccine raised blood-serum antibody levels significantly more than did a boost given by injection. Iran approved a COVID-19 vaccine administered as a nasal spray and made by the Razi Vaccine and Serum Research Institute in Karaj in October 2021.
ISSN:0028-0836
1476-4687
DOI:10.1038/d41586-022-02851-0